Explore News
-
What Drives the Success of Combination Therapy in HER2-Expressing Malignancies
A phase 1 study shows tolerable dosing schedule with promising activity for HER2-expressing malignancies
-
Why GSK’s New Cancer Drug is Causing a Stir
New treatment shows significant promise in reducing tumors
-
New Hope for Patients with Platinum-Resistant Ovarian Cancer
Clinical trial reveals promising results for Relacorilant in treating aggressive ovarian cancer
